Pfizer

The Past Week, In A Nutshell What Happened: Stocks closed the week practically unchanged after mixed reactions to a slew of blow-out earnings results. Remember This: “Although the stock market will certainly experience pullbacks, disappointments and corrections along the way, the horses have...

This morning's earnings include a few big names from disparate sectors: 3M Co (NYSE: MMM), Pfizer Inc. (NYSE: PFE), Pulte Group Inc. (NYSE: PHM), Lockheed Martin Corporation (NYSE: LMT), and United Technologies Corporation (NYSE: UTX). With headline news, especially...

Benzinga has examined the prospects for many investor favorite stocks over the past week. Bullish calls included an underappreciated automaker and a leading pharmaceutical. Bearish calls included FAANG stocks and an aerospace giant. Healthy earnings reports from sector leaders like Apple,...

Benzinga has examined prospects for many investor favorite stocks over the past week. Bullish calls included pharmaceutical and semiconductor leaders. And bearish calls included a fresh IPO and a struggling retailer. The first week of the second quarter was a relatively quiet one for the big three...

This weekend's Barron's cover story looks at why pharmaceutical giants are making big bets on gene therapy. See which companies already have been snapped up and which ones may be the next targets. Other notable articles offer a look at the implications of the tax law and a retirement guide...

Declining for the third month in a row, TD Ameritrade’s December Investor Movement Index (IMX) fell to a more than two-year low of 4.41 over the course of December. This is more than 16 percent below November’s reading of 5.27 and marks the steepest drop in the broker’s regular...

Benzinga has featured looks at many investor favorite stocks over the past week. The iPhone maker featured in both bullish and bearish calls after its reports. Other notable calls included a top automaker and e-commerce and pharma giants. A wild and spooky October for investors came to a close...

Pfizer Inc. (NYSE: PFE)'s pipeline consists of multiple growth assets that may be misunderstood by Wall Street analyst and investors. The Analyst Piper Jaffray's Richard Purkiss maintains an Overweight rating on Pfizer's stock with an unchanged $54 price target. The Thesis Pfizer...

You’ve seen the commercials: The antidepressant — oh, let’s call it Realitor — may cause suicide, explosive bowel syndrome, an erection lasting more than 72 days, lethargy, lumbago, listeria, hysteria, projectile vomiting and perhaps the plague. Consult your doctor if...

Shares of Pfizer Inc. (NYSE: PFE) were trading lower by nearly 2 percent Tuesday morning after analysts at Citi downgraded the stock and offered three alternative recommendations. Citi's Andrew Baum downgraded Pfizer's stock rating from Neutral to Sell with a price target slashed from $38 to $31....

Pharmaceutical M&A chatter has swirled this month. Short sellers have piled on to one possible buyer. Its share price rose in the first two weeks of February. Rumors that Pfizer Inc. (NYSE: PFE) had its eye on not just one acquisition but possibly two have helped lift the company...

The two pharmaceutical Dow components are expected to report earnings this week. Both of them are expected to show a decline in earnings from a year ago. Also, they both tend to exceed consensus earnings estimates. Most of the Dow Jones Industrial Average components have already...

More than a third of the Dow components are expected to report earnings this week. Only a health care giant and an oil supermajor are expected to show solid growth on both the top and bottom lines. Both have beat earnings expectations in recent quarters. We are in the heart of the fourth-quarter...

The cover story in this weekend's Barron's examines where to go and not go for yield in 2017. It's Barron's fifth annual assessment of income-producing investments in 10 sectors. Other featured articles offer Barron's latest picks and pans, as well as experts on...

This weekend's Barron's takes a look at the expected winners and losers following Donald Trump's election victory. The prospects for a leading biotechnology product development company and a prominent financial services company are also examined. Other featured stories offer...